Literature DB >> 12118904

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension.

Christian Delles1, Markus P Schneider, Stefan John, Michael Gekle, Roland E Schmieder.   

Abstract

BACKGROUND: Asymmetrical N(G), N(G)-dimethylarginine (ADMA) is associated with impaired endothelium-dependent vasodilation in humans.
METHODS: Twenty young, male, mildly hypertensive subjects were included in a randomized, double-blind, fourfold cross-over study with placebo, enalapril (20 mg/day), eprosartan (600 mg/day), or a combination of both drugs (10 and 300 mg/day, respectively) each over 1 week, followed by a 2-week wash-out phase. After each treatment phase, ADMA concentration was measured.
RESULTS: ADMA concentration was 1.69+/-0.59 micromol/L in the placebo phase, and was significantly lower in the enalapril, eprosartan, and combination phases (1.41+/-0.29, 1.42+/-0.43, and 1.38+/-0.30 micromol/L, respectively; all P < 0.05 v placebo). Changes in ADMA levels were independent of the drugs' action on blood pressure (BP).
CONCLUSIONS: Levels of ADMA were reduced with enalapril and eprosartan therapy. Our results suggest a specific action of these drugs on ADMA levels that is independent of BP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118904     DOI: 10.1016/s0895-7061(02)02278-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  26 in total

1.  Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.

Authors:  Feng-Ying Xu; Bo Yang; Duo Shi; Hao Li; Zui Zou; Xue-Yin Shi
Journal:  Eur J Clin Pharmacol       Date:  2011-09-01       Impact factor: 2.953

2.  The antihypertensive effect of arginine.

Authors:  Sudesh Vasdev; Vicki Gill
Journal:  Int J Angiol       Date:  2008

Review 3.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

4.  Asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Natasha C Moningka; Mark W Cunningham; Byron Croker; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-16       Impact factor: 3.619

5.  Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.

Authors:  Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Neil R Johnston; Jane Goddard; David J Webb
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

6.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05

7.  Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension.

Authors:  Dan Wang; Svend Strandgaard; Jens Iversen; Christopher S Wilcox
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-08-06       Impact factor: 3.619

8.  Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.

Authors:  Scott S Billecke; Louis G D'Alecy; Raylene Platel; Steven E Whitesall; Kenneth A Jamerson; Rachel L Perlman; Crystal A Gadegbeku
Journal:  Nephrol Dial Transplant       Date:  2008-09-15       Impact factor: 5.992

Review 9.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

Review 10.  Cellular ADMA: regulation and action.

Authors:  Tom Teerlink; Zaiming Luo; Fredrik Palm; Christopher S Wilcox
Journal:  Pharmacol Res       Date:  2009-08-12       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.